Implicity raises €35M from IRIS and Five Arrows to scale AI that cuts cardiac deaths by 26%

Implicity has pulled in €35 million in growth funding, with IRIS and Five Arrows leading the round. The Paris- and Cambridge, Massachusetts-based company says the money will go into its US push, more hiring, and possible acquisitions.

The pitch is straightforward, even if the product isn’t. Arnaud Rosier built Implicity after years of watching pacemaker and defibrillator alerts pile up faster than clinics could deal with them. He’s still working part-time as an electrophysiologist while running the company, nine years after founding it.

Implicity’s platform pulls in data from five device makers and hospital records, then feeds that into two AI products. Signal HF uses device data and France’s Health Data Hub to predict which patients may need hospitalisation. The other product, which Rosier calls productivity AI, is aimed at cutting false alarms by looking at medication history and clinical records.

The company says that work has translated into a 26% reduction in patient mortality. Signal HF got FDA approval about two years ago, after an earlier clearance in 2022 for a different ECG-analysis algorithm. On the company’s own telling, that mix of regulatory wins and clinical use is what gives it an edge, especially in the US, where Rosier says rivals tend to help clinics review device data rather than build their own medical AI.

The financing is not being framed as a takeover-style private equity deal. Rosier says Implicity avoided giving up a majority stake and picked investors who know how to help European companies scale in the US. The company says it now has around 120 to 125 employees, including 15 in the US and four in Germany, while its total funding since 2016 has reached about $69 million.